Skip to main content

CORRECTION article

Front. Pharmacol., 07 September 2022
Sec. Pharmacology of Anti-Cancer Drugs
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.964540
This article is part of the Research Topic Nanomaterials and Multimodal Tumor Therapy View all 45 articles

Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer

This article is a correction to:

  1. Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

    1. Read original article
Xing Feng,Xing Feng1,2Xiaoling XiongXiaoling Xiong3Shenglin Ma Shenglin Ma4*
  • 1Department of Thoracic Surgery, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China
  • 2Department of Thoracic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
  • 3Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
  • 4Department of Oncology, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, China

A Corrigendum on
Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer

by Feng X, Xiong X and Ma S (2022). Front. Pharmacol. 13:832725. doi: 10.3389/fphar.2022.832725

In the published article, there was an error in the author list. Author Xing Feng was erroneously listed as corresponding author. The corrected author list appears below:

“Xing Feng1,2, Xiaoling Xiong3 and Shenglin Ma4*

*Correspondence: Shenglin Ma, mashenglin0607@163.com”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: non-small cell lung cancer, targeted therapy, immunotherapy, photothermal therapy, cGAS-STING

Citation: Feng X, Xiong X and Ma S (2022) Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer. Front. Pharmacol. 13:964540. doi: 10.3389/fphar.2022.964540

Received: 08 June 2022; Accepted: 09 August 2022;
Published: 07 September 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Feng, Xiong and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shenglin Ma, mashenglin0607@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.